Skip to main content
SpringerLink
Log in

Medications and Cognition in Older Adults

  • Chapter
  • First Online:
Handbook on the Neuropsychology of Aging and Dementia

Part of the book series: Clinical Handbooks in Neuropsychology ((CHNEURO))

  • 6022 Accesses

Abstract

The elderly patient is particularly susceptible to negative effects on cognition that can arise from certain medications. This may occur whether or not pre-existing cognitive impairment is present. Medications whose primary target is the central nervous system (e.g., antidepressants, antipsychotics, sedative-hypnotics) or those which are targeted at other primary systems (e.g., cardiovascular drugs, urinary anti-spasmodics) should be considered as contributing factors in the patient with confusion or memory decline. Steps that can be taken to reduce this risk include: coordination of medical care among the patient’s clinicians to avoid polypharmacy, judicious selection of appropriate medications, use of the lowest effective drug dose, and substitution of non-pharmacologic therapies whenever possible. This chapter addresses potential complications of medication use in older adults with cognitive decline.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 349.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1.  Craig D, Passmore AP, Fullerton KJ, Beringer TR, Gilmore DH, Crawford VL, McCaffrey PM, Montgomery A. Factors influencing prescription of CNS medications in different elderly populations. Pharmacoepidemiol Drug Saf. 2003;12(5):383–7.

    PubMed  Google Scholar 

  2. Francis J. Delirium in older patients. J Am Geriatr Soc. 1992;40(8):829–38.

    PubMed  Google Scholar 

  3. Thompson II TL, Moran MG, Nies AS. Drug therapy: Psychotropic drug use in the elderly (first of two parts). N Engl J Med. 1983;308(3):134–8.

    PubMed  Google Scholar 

  4. Reynolds 3rd CF, Perel JM, Kupfer DJ, Zimmer B, Stack JA, Hoch CC. Open-trial response to antidepressant treatment in elderly patients with mixed depression and cognitive impairment. Psychiatry Res. 1987;21(2):111–22.

    PubMed  Google Scholar 

  5. Doraiswamy PM, Krishnan KR, Oxman T, Jenkyn LR, Coffey DJ, Burt T, Clary CM. Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci. 2003;58(12):M1137–44.

    PubMed  Google Scholar 

  6. Bartus RT, Dean 3rd RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408–14.

    PubMed  Google Scholar 

  7. Cole JO, Branconnier R, Salomon M, Dessain E. Tricyclic use in the cognitively impaired elderly. J Clin Psychiatry. 1983;44(9 Pt 2):14–9.

    PubMed  Google Scholar 

  8. Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry. 1983;44(5):173–6.

    PubMed  Google Scholar 

  9. Kumar S, Kulkarni SK. Influence of antidepressant drugs on learning and memory paradigms in mice. Indian J Exp Biol. 1996;34(5):431–5.

    PubMed  Google Scholar 

  10. Hoff AL, Shukla S, Helms P, Aronson TA, Logue C, Ollo C, Cook B. The effects of nortriptyline on cognition in elderly depressed patients. J Clin Psychopharmacol. 1990;10(3):231–2.

    PubMed  Google Scholar 

  11. Meyers BS, Mattis S, Gabriele M, Kakuma T. Effects of nortriptyline on memory self-assessment and performance in recovered elderly depressives. Psychophar­macol Bull. 1991;27(3):295–9.

    PubMed  Google Scholar 

  12. Young RC, Mattis S, Alexopoulos GS, Meyers BS, Shindledecker RD, Dhar AK. Verbal memory and plasma drug concentrations in elderly depressives treated with nortriptyline. Psychopharmacol Bull. 1991;27(3):291–4.

    PubMed  Google Scholar 

  13. Branconnier RJ, DeVitt DR, Cole JO, Spera KF. Amitriptyline selectively disrupts verbal recall from secondary memory of the normal aged. Neurobiol Aging. 1982;3(1):55–9.

    PubMed  Google Scholar 

  14. Teri L, Reifler BV, Veith RC, Barnes R, White E, McLean P, Raskind M. Imipramine in the treatment of depressed Alzheimer’s patients: impact on cognition. J Gerontol. 1991;46(6):P372–7.

    PubMed  Google Scholar 

  15. Podewils LJ, Lyketsos CG. Tricyclic antidepressants and cognitive decline. Psychosomatics. 2002;43(1):31–5.

    PubMed  Google Scholar 

  16. Knegtering H, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging. 1994;5(3):192–9.

    PubMed  Google Scholar 

  17. Savaskan E, Muller SE, Bohringer A, Schulz A, Schachinger H. Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients. Int J Neuropsychopharmacol. 2008;11(3):381–8.

    PubMed  Google Scholar 

  18. Finkel SI, Richter EM, Clary CM, Batzar E. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry. 1999;7(3):221–7.

    PubMed  Google Scholar 

  19. Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry. 2000;61(8):559–68.

    PubMed  Google Scholar 

  20. Cassano GB, Puca F, Scapicchio PL, Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry. 2002;63(5):396–402.

    PubMed  Google Scholar 

  21. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007;27(1):67–70.

    PubMed  Google Scholar 

  22. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871–80.

    PubMed  Google Scholar 

  23. Trick L, Stanley N, Rigney U, Hindmarch I. A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.I.D.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice. J Psychopharmacol. 2004;18(2):205–14.

    PubMed  Google Scholar 

  24. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900–9.

    PubMed  Google Scholar 

  25. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59(2):69–75.

    PubMed  Google Scholar 

  26. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.

    PubMed  Google Scholar 

  27. US Department of Health and Human Services. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Food and Drug Administration Web site.

    PubMed  Google Scholar 

  28. Stevenson DG, Decker SL, Dwyer LL, Huskamp HA, Grabowski DC, Metzger ED, Mitchell SL. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 national nursing home survey. Am J Geriatr Psychiatry. 2010;18(12):1078–92.

    PubMed  Google Scholar 

  29. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14(7):605–12.

    PubMed  Google Scholar 

  30. Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin. 2008;24(1):157–66.

    PubMed  Google Scholar 

  31. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–8.

    PubMed  Google Scholar 

  32. Burton LC, German PS, Rovner BW, Brant LJ. Physical restraint use and cognitive decline among nursing home residents. J Am Geriatr Soc. 1992;40(8):811–6.

    PubMed  Google Scholar 

  33. Woerner MG, Alvir JM, Kane JM, Saltz BL, Lieberman JA. Neuroleptic treatment of elderly patients. Psychopharmacol Bull. 1995;31(2):333–7.

    PubMed  Google Scholar 

  34. Steele C, Lucas MJ, Tune L. Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer’s type: preliminary findings. J Clin Psychiatry. 1986;47(6):310–2.

    PubMed  Google Scholar 

  35. Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer’s disease. Arch Neurol. 1989;46(8):854–7.

    PubMed  Google Scholar 

  36. Brown JW, Chobor A, Zinn F. Dementia testing in the elderly. J Nerv Ment Dis. 1993;181(11):695–8.

    PubMed  Google Scholar 

  37. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997;314(7076):266–70.

    PubMed  Google Scholar 

  38. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol. 1994;51(7):676–81.

    PubMed  Google Scholar 

  39. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56(10):1266–72.

    PubMed  Google Scholar 

  40. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7(1):70–6.

    PubMed  Google Scholar 

  41. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162–7.

    PubMed  Google Scholar 

  42. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR. The effect of clozapine on cognition and psychia­tric symptoms in patients with schizophrenia. Br J Psychiatry. 1993;162:43–8.

    PubMed  Google Scholar 

  43. Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer’s dementia. Int J Geriatr Psychiatry. 2005;20(11):1020–7.

    PubMed  Google Scholar 

  44. Savaskan E, Schnitzler C, Schroder C, Cajochen C, Muller-Spahn F, Wirz-Justice A. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer’s disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol. 2006;9(5):507–16.

    PubMed  Google Scholar 

  45. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002;16(2):128–30.

    PubMed  Google Scholar 

  46. Rainer MK, Masching AJ, Ertl MG, Kraxberger E, Haushofer M. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry. 2001;62(11):894–900.

    PubMed  Google Scholar 

  47. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.

    PubMed  Google Scholar 

  48. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844–54.

    PubMed  Google Scholar 

  49. Rocca P, Marino F, Montemagni C, Perrone D, Bogetto F. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer’s disease: preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci. 2007;61(6):622–9.

    PubMed  Google Scholar 

  50. De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, Iwamoto T. Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25(5):463–7.

    PubMed  Google Scholar 

  51. Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918–31.

    PubMed  Google Scholar 

  52. Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(7):537–50.

    PubMed  Google Scholar 

  53. Bain KT. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother. 2006;4(2):168–92.

    PubMed  Google Scholar 

  54. Bogunovic OJ, Greenfield SF. Practical geriatrics: use of benzodiazepines among elderly patients. Psychiatr Serv. 2004;55(3):233–5.

    PubMed  Google Scholar 

  55. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study. J Clin Psychopharmacol. 2002;22(3):285–93.

    PubMed  Google Scholar 

  56. Lagnaoui R, Begaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, Dartigues JF, Moride Y. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol. 2002;55(3):314–8.

    PubMed  Google Scholar 

  57. Dealberto MJ, McAvay GJ, Seeman T, Berkman L. Psychotropic drug use and cognitive decline among older men and women. Int J Geriatr Psychiatry. 1997;12(5):567–74.

    PubMed  Google Scholar 

  58. Brooks JO, Hoblyn JC. Neurocognitive costs and benefits of psychotropic medications in older adults. J Geriatr Psychiatry Neurol. 2007;20(4):199–214.

    PubMed  Google Scholar 

  59. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107(2):169–73.

    PubMed  Google Scholar 

  60. Foy A, Drinkwater V, March S, Mearrick P. Confusion after admission to hospital in elderly patients using benzodiazepines. Br Med J (Clin Res Ed). 1986;293(6554):1072.

    Google Scholar 

  61. Mokhber N, Azarpazhooh MR, Khajehdaluee M, Velayati A, Hopwood M. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2010;64(2):128–33.

    PubMed  Google Scholar 

  62. Hart RP, Colenda CC, Hamer RM. Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects. Am J Psychiatry. 1991;148(1):73–7.

    PubMed  Google Scholar 

  63. Cassidy EL, Lauderdale S, Sheikh JI. Mixed anxiety and depression in older adults: clinical characteristics and management. J Geriatr Psychiatry Neurol. 2005;18(2):83–8.

    PubMed  Google Scholar 

  64. Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl). 1994;116(2):130–4.

    Google Scholar 

  65. Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol. 2000;23(1):54–8.

    PubMed  Google Scholar 

  66. Stone JR, Zorick TS, Tsuang J. Dose-related illusions and hallucinations with zaleplon. Clin Toxicol (Phila). 2008;46(4):344–5.

    Google Scholar 

  67. Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol. 1999;13(1):18–31.

    PubMed  Google Scholar 

  68. Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, Mangano R. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol. 2000;20(3):328–37.

    PubMed  Google Scholar 

  69. Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, Verbaten MN, Paty I, Darwish M, Danjou P, Patat A. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22(6):576–83.

    PubMed  Google Scholar 

  70. Boyle J, Trick L, Johnsen S, Roach J, Rubens R. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol. 2008;23(5):385–97.

    PubMed  Google Scholar 

  71. Allain H, Bentue-Ferrer D, Tarral A, Gandon JM. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol. 2003;59(3):179–88.

    PubMed  Google Scholar 

  72. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol. 1992;43(6):597–601.

    PubMed  Google Scholar 

  73. Otmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N, Staner L. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008;23(8):693–705.

    PubMed  Google Scholar 

  74. Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161(17):2091–7.

    PubMed  Google Scholar 

  75. Basu R, Dodge H, Stoehr GP, Ganguli M. Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. Am J Geriatr Psychiatry. 2003;11(2):205–13.

    PubMed  Google Scholar 

  76. McEvoy LK, Smith ME, Fordyce M, Gevins A. Characterizing impaired functional alertness from diphenhydramine in the elderly with performance and neurophysiologic measures. Sleep. 2006;29(7):957–66.

    PubMed  Google Scholar 

  77. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469–76.

    PubMed  Google Scholar 

  78. Peck JS, LeGoff DB, Ahmed I, Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry. 2004;12(4):432–6.

    PubMed  Google Scholar 

  79. Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299(22):2642–55.

    PubMed  Google Scholar 

  80. Molloy SA, Rowan EN, O’Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(12):1323–8.

    PubMed  Google Scholar 

  81. Morrison CE, Borod JC, Brin MF, Halbig TD, Olanow CW. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD). J Neural Transm. 2004;111(10–11):1333–41.

    PubMed  Google Scholar 

  82. Radbill R, Rosenberg G, Schwartz A. Effects of levodopa therapy in Parkinson’s disease. II. Measurement of behavioural changes. Can Med Assoc J. 1974;111(11):1218–22.

    PubMed  Google Scholar 

  83. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain. 1992;115(Pt 6):1701–25.

    PubMed  Google Scholar 

  84. Portin R, Rinne UK. The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment. Acta Neurol Scand Suppl. 1983;95:135–44.

    PubMed  Google Scholar 

  85. Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006;248(1–2):78–83.

    PubMed  Google Scholar 

  86. Brusa L, Bassi A, Stefani A, Pierantozzi M, Peppe A, Caramia MD, Boffa L, Ruggieri S, Stanzione P. Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm. 2003;110(4):373–80.

    PubMed  Google Scholar 

  87. Brusa L, Tiraboschi P, Koch G, Peppe A, Pierantozzi M, Ruggieri S, Stanzione P. Pergolide effect on ­cognitive functions in early-mild Parkinson’s disease. J Neural Transm. 2005;112(2):231–7.

    PubMed  Google Scholar 

  88. Costa A, Peppe A, Dell’Agnello G, Caltagirone C, Carlesimo GA. Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia. 2009;47(5):1374–81.

    PubMed  Google Scholar 

  89. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.

    PubMed  Google Scholar 

  90. Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during tolcapone treatment in Parkinson’s disease. J Neural Transm. 1997;104(8–9):887–94.

    PubMed  Google Scholar 

  91. Hokendorf H. Combination therapy of extrapyramidal disease with trihexyphenidyl and l-dopa: an electromyographic study with specific reference to tremor. J Int Med Res. 1979;7(1):19–28.

    PubMed  Google Scholar 

  92. Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol. 1986;43(2):126–7.

    PubMed  Google Scholar 

  93. Wirshing WC, Freidenberg DL, Cummings JL, Bartzokis G. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychopharmacol. 1989;9(6):407–11.

    PubMed  Google Scholar 

  94. Bedard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y. Acute and long-term administration of anticholinergics in Parkinson’s disease: specific effects on the subcortico-frontal syndrome. Brain Cogn. 1999;40(2):289–313.

    PubMed  Google Scholar 

  95. Van Spaendonck KP, Berger HJ, Horstink MW, Buytenhuijs EL, Cools AR. Impaired cognitive ­shifting in parkinsonian patients on anticholinergic therapy. Neuropsychologia. 1993;31(4):407–11.

    PubMed  Google Scholar 

  96. Fayen M, Goldman MB, Moulthrop MA, Luchins DJ. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Am J Psychiatry. 1988;145(4):483–6.

    PubMed  Google Scholar 

  97. Heinik J. Effects of trihexyphenidyl on MMSE and CAMCOG scores of medicated elderly patients with schizophrenia. Int Psychogeriatr. 1998;10(1):103–8.

    PubMed  Google Scholar 

  98. Meador KJ. Cognitive side effects of medications. Neurol Clin. 1998;16(1):141–55.

    PubMed  Google Scholar 

  99. Drane DL, Meador KJ. Epilepsy, anticonvulsant drugs and cognition. Baillieres Clin Neurol. 1996;5(4):877–85.

    PubMed  Google Scholar 

  100. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B. Results of a nationwide veterans administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia. 1987;28 Suppl 3:S50–8.

    PubMed  Google Scholar 

  101. Prevey ML, Delaney RC, Cramer JA, Cattanach L, Collins JF, Mattson RH. Effect of valproate on cognitive functioning. Comparison with carbamazepine. The department of veterans affairs epilepsy cooperative study 264 group. Arch Neurol. 1996;53(10):1008–16.

    PubMed  Google Scholar 

  102. Read CL, Stephen LJ, Stolarek IH, Paul A, Sills GJ, Brodie MJ. Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study. Seizure. 1998;7(2):159–62.

    PubMed  Google Scholar 

  103. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia. 1994;35(2):381–90.

    PubMed  Google Scholar 

  104. Profenno LA, Jakimovich L, Holt CJ, Porsteinsson A, Tariot PN. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with ­probable Alzheimer’s disease. Curr Alzheimer Res. 2005;2(5):553–8.

    PubMed  Google Scholar 

  105. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54–61.

    PubMed  Google Scholar 

  106. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav. 2010;17(4):461–6.

    PubMed  Google Scholar 

  107. Gomer B, Wagner K, Frings L, Saar J, Carius A, Harle M, Steinhoff BJ, Schulze-Bonhage A. The influence of antiepileptic drugs on cognition: a ­comparison of levetiracetam with topiramate. Epilepsy Behav. 2007;10(3):486–94.

    PubMed  Google Scholar 

  108. Romigi A, Cervellino A, Marciani MG, Izzi F, Massoud R, Corona M, Torelli F, Zannino S, Uasone E, Placidi F. Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur J Neurol. 2008;15(2):190–5.

    PubMed  Google Scholar 

  109. Kececi H, Atakay S. Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients. J Clin Neurosci. 2009;16(12):1588–91.

    PubMed  Google Scholar 

  110. Menefee LA, Frank ED, Crerand C, Jalali S, Park J, Sanschagrin K, Besser M. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med. 2004;5(1):42–9.

    PubMed  Google Scholar 

  111. Blumstein H, Gorevic PD. Rheumatologic illnesses: treatment strategies for older adults. Geriatrics. 2005;60(6):28–35.

    PubMed  Google Scholar 

  112. Ng KF, Yuen TS, Ng VM. A comparison of postoperative cognitive function and pain relief with fentanyl or tramadol patient-controlled analgesia. J Clin Anesth. 2006;18(3):205–10.

    PubMed  Google Scholar 

  113. Kunig G, Datwyler S, Eschen A, Schreiter Gasser U. Unrecognised long-lasting tramadol-induced delirium in two elderly patients. A case report. Pharmacopsychiatry. 2006;39(5):194–9.

    PubMed  Google Scholar 

  114. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag. 2006;2(3):137–46.

    PubMed  Google Scholar 

  115. Fong HK, Sands LP, Leung JM. The role of postoperative analgesia in delirium and cognitive decline in elderly patients: a systematic review. Anesth Analg. 2006;102(4):1255–66.

    PubMed  Google Scholar 

  116. Manning C, Scandale L, Manning EJ, Gengo FM. Central nervous system effects of meclizine and dimenhydrinate: evidence of acute tolerance to ­antihistamines. J Clin Pharmacol. 1992;32(11):996–1002.

    PubMed  Google Scholar 

  117. Molloy DW. Memory loss, confusion, and disorientation in an elderly woman taking meclizine. J Am Geriatr Soc. 1987;35(5):454–6.

    PubMed  Google Scholar 

  118. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller 3rd EA, Murphy DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry. 1987;44(5):418–26.

    PubMed  Google Scholar 

  119. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic-dependent cognitive deficits in Parkinson’s disease. Ann Neurol. 1987;22(1):26–30.

    PubMed  Google Scholar 

  120. Zemishlany Z, Thorne AE. Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects. Isr J Psychiatry Relat Sci. 1991;28(3):32–41.

    PubMed  Google Scholar 

  121. de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer’s disease? Neurol Res. 2006;28(6):637–44.

    PubMed  Google Scholar 

  122. Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy. 2008;28(3):366–75.

    PubMed  Google Scholar 

  123. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009;7(5):250–61.

    PubMed  Google Scholar 

  124. Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985;28(Suppl):55–63.

    PubMed  Google Scholar 

  125. Neil-Dwyer G, Bartlett J, McAinsh J, Cruickshank JM. Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol. 1981;11(6):549–53.

    PubMed  Google Scholar 

  126. Cove-Smith JR, Kirk CA. CNS-related side-effects with metoprolol and atenolol. Eur J Clin Pharmacol. 1985;28(Suppl):69–72.

    PubMed  Google Scholar 

  127. McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46(2):163–97.

    PubMed  Google Scholar 

  128. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, Greenlick MR, Hadley E, Moye L, Perry Jr HM, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154(19):2154–60.

    PubMed  Google Scholar 

  129. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003;17(11):781–5.

    PubMed  Google Scholar 

  130. Perez-Stable EJ, Halliday R, Gardiner PS, Baron RB, Hauck WW, Acree M, Coates TJ. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. Am J Med. 2000;108(5):359–65.

    PubMed  Google Scholar 

  131. Palac DM, Cornish RD, McDonald WJ, Middaugh DA, Howieson D, Bagby SP. Cognitive function in hypertensives treated with atenolol or propranolol. J Gen Intern Med. 1990;5(4):310–8.

    PubMed  Google Scholar 

  132. Gliebus G, Lippa CF. The influence of beta-blockers on delayed memory function in people with cognitive impairment. Am J Alzheimers Dis Other Demen. 2007;22(1):57–61.

    PubMed  Google Scholar 

  133. Portnoi VA. Digitalis delirium in elderly patients. J Clin Pharmacol. 1979;19(11–12):747–50.

    PubMed  Google Scholar 

  134. Eisendrath SJ, Sweeney MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry. 1987;144(4):506–7.

    PubMed  Google Scholar 

  135. Laudisio A, Marzetti E, Pagano F, Cocchi A, Bernabei R, Zuccala G. Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey. Drugs Aging. 2009;26(2):103–12.

    PubMed  Google Scholar 

  136. Salom IL, Silvis SE, Doscherholmen A. Effect of cimetidine on the absorption of vitamin B12. Scand J Gastroenterol. 1982;17(1):129–31.

    PubMed  Google Scholar 

  137. Force RW, Nahata MC. Effect of histamine h2-receptor antagonists on vitamin B12 absorption. Ann Pharmacother. 1992;26(10):1283–6.

    PubMed  Google Scholar 

  138. Wolters M, Strohle A, Hahn A. Cobalamin: a critical vitamin in the elderly. Prev Med. 2004;39(6):1256–66.

    PubMed  Google Scholar 

  139. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422–8.

    PubMed  Google Scholar 

  140. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162–7.

    PubMed  Google Scholar 

  141. Boustani M, Hall KS, Lane KA, Aljadhey H, Gao S, Unverzagt F, Murray MD, Ogunniyi A, Hendrie H. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc. 2007;55(8):1248–53.

    PubMed  Google Scholar 

  142. Oslin DW, Katz IR, Sands LP, Bilker W, DiFilippo SD, D’Angelo K. Examination of the cognitive effects of cimetidine in normal elderly volunteers. Am J Geriatr Psychiatry. 1999;7(2):160–5.

    PubMed  Google Scholar 

  143. Hanlon JT, Landerman LR, Artz MB, Gray SL, Fillenbaum GG, Schmader KE. Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly. Pharma­coepidemiol Drug Saf. 2004;13(11):781–7.

    PubMed  Google Scholar 

  144. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62(11):1792–800.

    PubMed  Google Scholar 

  145. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009;8(6):615–26.

    PubMed  Google Scholar 

  146. Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, Steel M. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317–26.

    PubMed  Google Scholar 

  147. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173(2):493–8.

    PubMed  Google Scholar 

  148. Womack KB, Heilman KM. Tolterodine and ­memory: dry but forgetful. Arch Neurol. 2003;60(5):771–3.

    PubMed  Google Scholar 

  149. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4):319–32.

    PubMed  Google Scholar 

  150. Coluccia D, Wolf OT, Kollias S, Roozendaal B, Forster A, de Quervain DJ. Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. J Neurosci. 2008;28(13):3474–8.

    PubMed  Google Scholar 

  151. Varney NR, Alexander B, MacIndoe JH. Reversible steroid dementia in patients without steroid psychosis. Am J Psychiatry. 1984;141(3):369–72.

    PubMed  Google Scholar 

  152. Sacks O, Shulman M. Steroid dementia: an overlooked diagnosis? Neurology. 2005;64(4):707–9.

    PubMed  Google Scholar 

  153. Gupta VP, Ehrlich GE. Organic brain syndrome in rheumatoid arthritis following corticosteroid withdrawal. Arthritis Rheum. 1976;19(6):1333–8.

    PubMed  Google Scholar 

  154. Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med. 1991;151(7):1309–13.

    PubMed  Google Scholar 

  155. Price JF, Stewart MC, Deary IJ, Murray GD, Sandercock P, Butcher I, Fowkes FG. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ. 2008;337:a1198.

    PubMed  Google Scholar 

  156. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women’s health study cognitive cohort. BMJ. 2007;334(7601):987.

    PubMed  Google Scholar 

  157. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer’s disease anti-inflammatory prevention trial (adapt): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65(7):896–905.

    PubMed  Google Scholar 

  158. Small GW, Siddarth P, Silverman DH, Ercoli LM, Miller KJ, Lavretsky H, Bookheimer SY, Huang SC, Barrio JR, Phelps ME. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am J Geriatr Psychiatry. 2008;16(12):999–1009.

    PubMed  Google Scholar 

  159. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: the epidemiological evidence. CNS Neurol Disord Drug Targets. 2010;9(2):132–9.

    PubMed  Google Scholar 

  160. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam study. Neurology. 1995;45(8):1441–5.

    PubMed  Google Scholar 

  161. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology. 1995;45(1):51–5.

    PubMed  Google Scholar 

  162. Sturmer T, Glynn RJ, Field TS, Taylor JO, Hennekens CH. Aspirin use and cognitive function in the elderly. Am J Epidemiol. 1996;143(7):683–91.

    PubMed  Google Scholar 

  163. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997;48(3):626–32.

    PubMed  Google Scholar 

  164. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology. 2004;23(4):159–69.

    PubMed  Google Scholar 

  165. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDS on the development of Alzheimer disease. Neurology. 2008;70(19):1672–7.

    PubMed  Google Scholar 

  166. Waldstein SR, Wendell CR, Seliger SL, Ferrucci L, Metter EJ, Zonderman AB. Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc. 2010;58(1):38–43.

    PubMed  Google Scholar 

  167. Hanlon JT, Schmader KE, Landerman LR, Horner RD, Fillenbaum GG, Pieper CF, Wall Jr WE, Koronkowski MJ, Cohen HJ. Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. Ann Epidemiol. 1997;7(2):87–94.

    PubMed  Google Scholar 

  168. Henderson AS, Jorm AF, Christensen H, Jacomb PA, Korten AE. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry. 1997;12(9):926–30.

    PubMed  Google Scholar 

  169. Saag KG, Rubenstein LM, Chrischilles EA, Wallace RB. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol. 1995;22(11):2142–7.

    PubMed  Google Scholar 

  170. Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, Larson EB. Risk of dementia and ad with prior exposure to NSAIDS in an elderly community-based cohort. Neurology. 2009;72(22):1899–905.

    PubMed  Google Scholar 

  171. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD003122.

    Google Scholar 

  172. Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, Johnston J, Karlamangla AS. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850–7.

    PubMed  Google Scholar 

  173. Coker LH, Espeland MA, Rapp SR, Legault C, Resnick SM, Hogan P, Gaussoin S, Dailey M, Shumaker SA. Postmenopausal hormone therapy and cognitive outcomes: the women’s health initiative memory study (WHIMS). J Steroid Biochem Mol Biol. 2010;118(4–5):304–10.

    PubMed  Google Scholar 

  174. Moffat SD. Effects of testosterone on cognitive and brain aging in elderly men. Ann N Y Acad Sci. 2005;1055:80–92.

    PubMed  Google Scholar 

  175. Fuller SJ, Tan RS, Martins RN. Androgens in the etiology of Alzheimer’s disease in aging men and possible therapeutic interventions. J Alzheimers Dis. 2007;12(2):129–42.

    PubMed  Google Scholar 

  176. Warren MF, Serby MJ, Roane DM. The effects of testosterone on cognition in elderly men: a review. CNS Spectr. 2008;13(10):887–97.

    PubMed  Google Scholar 

  177. Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl. 2007;28(6):875–82.

    PubMed  Google Scholar 

  178. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39–52.

    PubMed  Google Scholar 

  179. Mitsiades N, Correa D, Gross CP, Hurria A, Slovin SF. Cognitive effects of hormonal therapy in older adults. Semin Oncol. 2008;35(6):569–81.

    PubMed  Google Scholar 

  180. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64(2):165–76.

    PubMed  Google Scholar 

  181. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26(7):955–69.

    PubMed  Google Scholar 

  182. Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17(2):309–14.

    PubMed  Google Scholar 

  183. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106.

    PubMed  Google Scholar 

  184. Matousek RH, Sherwin BB. A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology. 2010;35(2):215–25.

    PubMed  Google Scholar 

  185. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59(3):378–84.

    PubMed  Google Scholar 

  186. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, Kuller L. Statins and cognitive function in the elderly: the cardiovascular health study. Neurology. 2005;65(9):1388–94.

    PubMed  Google Scholar 

  187. Willey JZ, Elkind MS. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol. 2010;67(9):1062–7.

    PubMed  Google Scholar 

  188. Rogers RL, Meyer JS, McClintic K, Mortel KF. Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion. Angiology. 1989;40(4 Pt 1):260–9.

    PubMed  Google Scholar 

  189. Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, Bennett DA, Wilson RS, Aggarwal N. Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. J Neurol Neurosurg Psychiatry. 2004;75(8):1093–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurology, Westchester Health Associates, Yorktown Heights, NY, 10598, USA

    Gregg L. Caporaso M.D., Ph.D.

Authors
  1. Gregg L. Caporaso M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. East 72 Street, STE 500 428, New York, 10021, New York, USA

    Lisa D. Ravdin

  2. Miller School of Medicine, University of Miami, NW. 14th Street 1120, Miami, 33136, Florida, USA

    Heather L. Katzen

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Caporaso, G.L. (2013). Medications and Cognition in Older Adults. In: Ravdin, L., Katzen, H. (eds) Handbook on the Neuropsychology of Aging and Dementia. Clinical Handbooks in Neuropsychology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3106-0_7

Download citation

Publish with us

Policies and ethics

Search

Navigation